Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)
LL-37: Evidence Summary
Evidence summary for LL-37 across studied indications. Each indication is graded using our evidence tier system based on the quality and quantity of available clinical data.
Back to LL-37 overview| Indication | Evidence Tier | Trial Count | Summary |
|---|---|---|---|
| Antimicrobial defense | Tier C | 2 | Human cathelicidin with broad-spectrum activity; clinical use data emerging |
| Wound healing | Tier D | 1 | Promotes re-epithelialization and angiogenesis in preclinical wound models |